Semax, a synthetic heptapeptide derived from ACTH, modulates the hypothalamic-pituitary-adrenal (HPA) axis through a variety of mechanisms that include neuroprotection, modulation of gene expression, activation of key neurotransmitter systems, and immune system effects. Unlike full-length ACTH, Semax’s primary action is indirect and central, aiming to normalize dysregulated stress responses rather than directly stimulating adrenal corticosteroid release. It achieves this by influencing the expression of BDNF and TrkB receptor, activating dopaminergic and serotonergic stems, exhibiting antidepressant and anxiolytic effects, antagonizing melanocortin receptors, and promoting the survival of neurons during hypoxia and glutamate neurotoxicity [1].
What the AI assistants say
AI assistants collectively agree that Semax does not directly activate the HPA axis like ACTH. Instead, it normalizes HPA tone by suppressing chronic HPA hyperactivity, primarily through melanocortin receptor antagonism/partial agonism in the hypothalamus, leading to reduced CRH mRNA expression and downstream decreases in ACTH and cortisol/corticosterone [2]. They also agree that Semax is non-corticotropic, meaning it has no adrenal corticostimulating effect and does not elevate cortisol in unstressed states [3]. Furthermore, AI assistants concur that Semax increases dopamine and serotonin activity, which indirectly normalizes the HPA-HPG axis interaction [2]. They also highlight that Semax elevates hippocampal BDNF mRNA/protein, which enhances glucocorticoid receptor expression and strengthens negative feedback [2].
What the research actually shows
The research underscores Semax’s multifaceted approach to modulating the HPA axis [1]. Firstly, Semax is described as a neuroprotective agent that contributes to mitochondrial stability under stress conditions induced by the deregulation of calcium ion flow [1]. This suggests that Semax may help maintain cellular homeostasis, which could indirectly influence the HPA axis, as this axis is sensitive to cellular stress and damage.
Secondly, Semax elevates the expression of brain-derived neurotrophic factor (BDNF) and the TrkB receptor [1]. BDNF is known to play a role in the modulation of the HPA axis, and by increasing its expression, Semax may influence the activity of this axis.
Thirdly, Semax activates dopaminergic and serotonergic stems [1]. Both dopamine and serotonin are neurotransmitters that have been implicated in the regulation of the HPA axis. For instance, serotonin is known to stimulate the release of corticotropin-releasing hormone (CRH) from the hypothalamus, which in turn triggers the release of ACTH from the pituitary gland, ultimately leading to the production of cortisol from the adrenal cortex [7].
Fourthly, Semax can work as an antidepressant and an anxiolytic, attenuating chronic stress effects [1]. This is significant because chronic stress is a major factor that can dysregulate the HPA axis, leading to increased cortisol production and a range of stress-related disorders.
Fifthly, Semax is a potential melanocortin antagonist (MC3R, MC4R) [1]. Melanocortins, such as ACTH, are known to influence the HPA axis. By antagonizing melanocortin receptors, Semax may modulate the effects of melanocortins on the HPA axis.
Sixthly, in a study on brain focal ischemia, Semax influenced the expression of genes that promote the formation and functioning of the vascular system [1]. This suggests that Semax may have a role in modulating gene expression, which could include genes involved in the HPA axis.
Seventhly, Semax promotes the survival of neurons during hypoxia and glutamate neurotoxicity [1]. Neurons in the hypothalamus play a crucial role in the regulation of the HPA axis, and the survival and health of these neurons are essential for the proper functioning of the axis.
Lastly, Semax increases the amount and mobility of immune cells and enhances the expression of chemokine and immunoglobulin genes [1]. The immune system is closely linked with the HPA axis, and immune challenges can trigger the activation of the HPA axis.
Where AI and research diverge
While AI assistants and the research agree on several points regarding Semax’s mechanism of action on the HPA axis, there are some divergences. AI assistants emphasize Semax’s role in suppressing chronic HPA hyperactivity and its non-corticotropic property, while the research provides a more detailed view of Semax’s neuroprotective effects, influence on gene expression, and effects on immune system function. The research also highlights Semax’s role in promoting neuronal survival and its potential as a melanocortin antagonist, which are not mentioned by the AI assistants.
Bottom line: Semax influences the HPA axis through multiple mechanisms, including neuroprotection, modulation of gene expression, activation of dopaminergic and serotonergic systems, and immune system effects, thereby playing a role in stress response and homeostasis regulation.
References
- Basic and Clinical Aspects of Growth Hormone
- Developmental trauma disorder_ toward a rational diagnosis for children with complex trauma histories
- Endocrinology_ Adult and Pediatric
- Gene Therapy in Neurological Diseases
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Growth Hormone Secretagogues in Clinical Practice
- Handbook of Biologically Active Peptides
- Hypothalamic Integration of Energy Metabolism
- Life Force
- Molecular Neuroscience
- Neuroanatomy of Metabolic Control
- Peptide Protocols Volume One — William A Seeds MD
- Selenium_ Its Molecular Biology and Role in Human Health
- The Developmental Capacity of Nuclei
Continue your research
Part of our Semax: Mechanisms & How It Works guide.
- How does Semax exert its neuroprotective effects?
- How does Semax modulate the release of stress-related hormones?
- How does Semax influence the expression of genes related to neuroprotection?
Related topics:
- How does Semax compare to other cognitive enhancers in terms of mechanism of action and side effects?
- How does Semax influence wound healing processes?
- What role does Semax play in promoting recovery from traumatic brain injury?